PARABOLIC DRUGS (India) Financial Analysis

<div class='circular--portrait' style='background:#2A0CD0;color: white;font-size:4em;padding-top: 25px;;'>PA</div>
The current investor indifference towards the small price fluctuations of PARABOLIC DRUGS may encourage investors to take a closer look at the entity as it closed today at a share price of 0.0 on very low momentum in trading volume. The company executives did not add any value to PARABOLIC DRUGS investors in January. However, most investors can still diversify their portfolios with PARABOLIC DRUGS to hedge your portfolio against high-volatility market scenarios. The stock standard deviation of daily returns for 30 days (very short) investing horizon is currently 0.0. The very small Stock volatility is a good signal to investors with longer term investment horizons. The PARABOLIC DRUGS financial analysis interface makes it easy to digest most current publicly released information about PARABOLIC DRUGS as well as get updates on important government artifacts including earning estimates, SEC corporate filings and announcements. This module also helps to analyze PARABOLIC DRUGS price relationship with some important fundamental indicators such as market cap and management efficiency. Check out Your Equity Center.


The company recorded loss per share of 9.3. PARABOLIC DRUGS last dividend was issued on 2012-09-24. Parabolic Drugs Limited develops, manufactures, and sells active pharmaceutical ingredients and API intermediates in India. Parabolic Drugs Limited was founded in 1996 and is based in Chandigarh, India. PARABOLIC DRUGS operates under Drug Manufacturers - Specialty Generic classification in India and is traded on National Stock Exchange of India. It employs 1011 people. To find out more about N/A contact the company at 91 17 2418 2800 or learn more at http://www.parabolicdrugs.com.


PARABOLIC DRUGS is not yet fully synchronised with the market data
PARABOLIC DRUGS has some characteristics of a very speculative penny stock
PARABOLIC DRUGS has high likelihood to experience some financial distress in the next 2 years
PARABOLIC DRUGS has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations
The company has accumulated 4.21 B in total debt with debt to equity ratio (D/E) of 265.1 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. PARABOLIC DRUGS has Current Ratio of 0.19 indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due.
The entity reported revenue of 731.57 M. Net Loss for the year was (575.48 M) with profit before overhead, payroll, taxes, and interest of 92.9 M.

Market Capitalization

The company currently falls under 'Micro-Cap' category with current market capitalization of 55.7 M.


The company has Profit Margin (PM) of (78.66) % which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (69.0) % which suggests for every $100 dollars of sales it generated a net operating loss of -0.69.

Management Efficiency

PARABOLIC DRUGS has return on total asset (ROA) of (7.07) % which means that it has lost $7.07 on every $100 spent on asset. This is way below average.

PARABOLIC DRUGS Technical and Predictive Indicators

Did you try this?

Run Idea Breakdown Now


Idea Breakdown

Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
All  Next Launch Module
Check out Your Equity Center. Please also try Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Company logos by clearbit